Sort
8,912 grants matching “sars cov 2”
virtual compound screening using gene expression
$420,807Bin Chen · Michigan State University · R01 · FY2022 · GM
virtual compound screening using gene expression
$420,807Bin Chen · Michigan State University · R01 · FY2024 · GM
Immunomodulatory effects of coronavirus membrane proteins E, M, and S.
$420,750Edward Brice Stephens · University Of Kansas Medical Center · R21 · FY2020 · AI
Investigating Lung Injury After Cervical Spinal Cord Injury
$420,750Warren Joseph Alilain · University Of Kentucky · R21 · FY2021 · NS
Exosome-display as a strategy to enhance the immunogenicity of SARS-CoV-2 vaccines based on adenoviral vectors
$420,520Lynda Coughlan · University Of Maryland Baltimore · R21 · FY2020 · AI
Phase IbTrial of Rintatolimod and IFNa Regimen in Cancer Patients with Mild or Moderate COVID-19 infection
$420,500Candace S Johnson · Roswell Park Cancer Institute Corp · P30 · FY2020 · CA
Molecular Characterization of the SARS-CoV-2 Helicase and High-Throughput Screening to Identify Small Molecule SARS-CoV-2 Helicase Inhibitors as Anti-Viral Medicines
$420,200Robert Brosh · National Institute On Aging · ZIA · FY2025 · AG
Point-of-Collection Sample Pretreatment and Preservation with Porous Super-Absorbent Polymer (PSAP) Beads for Wastewater Surveillance Testing
$420,000Xing Xie · Georgia Tech Research Corporation · · FY2023 · ENG
Helping Us Grow Stronger (HUGS/Abrazos): COVID-19 in pregnancy and reducing toxic stress in mother-infant dyads
$419,987Andrea Goldberg Edlow · Massachusetts General Hospital · R01 · FY2021 · HD
Statistical Methods in COVID-19/PASC Clinical Research
$419,861Andrea Sarah Foulkes · Massachusetts General Hospital · R01 · FY2024 · HL
Semiparametric Regression Analysis of Interval-Censored Data in Current Cohort Studies
$419,787Donglin Zeng · University Of Michigan At Ann Arbor · R01 · FY2025 · HL
Systems Immunogenetics of Emerging Coronavirus Infections in the Collaborative Cross
$419,667Ralph S Baric · Univ Of North Carolina Chapel Hill · U19 · FY2018 · AI
Targeting the neuropilin-1 receptor (NRP-1)/VEGF-A axis for neuropathic pain
$419,470Rajesh Khanna · Regulonix, Llc · R41 · FY2021 · NS
Prepare Bioanalytical Aptamer Tools and Train Next-generation Scientists for SARS-CoV-3
$419,466Xiaohong Tan · Bowling Green State University · R15 · FY2025 · AI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older
$419,442Peter B. Gilbert · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
Can SARS-CoV-2 proteins accelerate Abeta pathology in fly and mouse models of AD?
$419,375Diego E Rincon-Limas · University Of Florida · R21 · FY2025 · AG
Statistical Methods in COVID-19/PASC Clinical Research
$419,114Andrea Sarah Foulkes · Massachusetts General Hospital · R01 · FY2025 · HL
Indentification and characterization of cellular receptors for enveloped viruses
$418,975Michael R. Farzan · Harvard Medical School · U54 · FY2011 · AI
Mechanisms of Dysregulated Innate Immune Responses to Lethal Infections
$418,750Haichao Wang · Feinstein Institute For Medical Research · R35 · FY2024 · GM
Mechanisms of Dysregulated Innate Immune Responses to Lethal Infections
$418,750Haichao Wang · Feinstein Institute For Medical Research · R35 · FY2022 · GM
Mechanisms of Dysregulated Innate Immune Responses to Lethal Infections
$418,750Haichao Wang · Feinstein Institute For Medical Research · R35 · FY2025 · GM
Endotheliopathy and liver injury in COVID-19
$418,750Yasuko Iwakiri · Yale University · R01 · FY2021 · DK
Mechanisms of Dysregulated Innate Immune Responses to Lethal Infections
$418,750Haichao Wang · Feinstein Institute For Medical Research · R35 · FY2023 · GM
Endotheliopathy and liver injury in COVID-19
$418,750Yasuko Iwakiri · Yale University · R01 · FY2023 · DK
Endotheliopathy and liver injury in COVID-19
$418,750Yasuko Iwakiri · Yale University · R01 · FY2022 · DK